In Spain, more than 75.000 persons have died of COVID-19, predominantly in densely populated regions like Madrid and Barcelona.

The Spanish Agency of Medicines and Medical Devices (Agencia Española de Medicamentos y Productos Sanitarios) has recently authorized the start of a clinical investigation designed to collect data to assess the safety and performance of Seraph® 100 Microbind Affinity Blood Filter (Seraph 100) in the treatment of 42 patients with COVID-19. Hospital Clínico San Carlos (Madrid) and Hospital Universitari Vall d’Hebron (Barcelona) will participate in this clinical investigation, together with some German centers.

Seraph 100 is a single use extracorporeal broadspectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. The Seraph 100 filter has been shown in an in-vitro study to provide clearance of coronavirus from the blood. The use of this extracorporeal filter to remove SARS-CoV-2 virus from the blood is expected to reduce the viral load and shorten or even prevent viral sepsis in patients with COVID-19.

We at Cardiolink Group, as Seraph 100’s Spanish distributor, are thrilled to support Exthera Medical and ÅKRN Scientific Consulting with the implementation of this study to ensure that reliable and accurate data is presented as soon as possible.